Overview

An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function

Status:
Completed
Trial end date:
2019-06-24
Target enrollment:
0
Participant gender:
All
Summary
This is an investigational study to evaluate the experimental medication BMS-986036 in participants with different levels of kidney function.
Phase:
Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Bristol-Myers Squibb
Criteria
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com

Inclusion Criteria:

- BMI ≥ 25 and ≤ 40 kg/m2

Exclusion Criteria:

- Presence of any factors that would predispose the participant to infection (eg,
extensive periodontal disease that warrants surgical or medical treatment, unhealed
open wounds)

- Any bone trauma (fracture) or bone surgery (ie, hardware placement, joint replacement,
bone grafting, or amputation) within 3 months of study drug administration

- Any history of known or suspected congenital or acquired immunodeficiency state or
condition that would compromise the participant's immune status

- Any major surgery (eg, abdominal, thoracal, or cranial procedures) within 6 weeks of
study drug administration

- Donation of blood or plasma to a blood bank, or in a clinical study (except at the
screening visit) within 6 weeks of study drug administration

- Inability to tolerate subcutaneous injections

Other protocol defined inclusion/exclusion criteria could apply